LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

Search

Emergent BioSolutions Inc

Avatud

SektorTervishoid

7.82 -1.14

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.74

Max

7.99

Põhinäitajad

By Trading Economics

Sissetulek

-80M

-12M

Müük

-81M

141M

P/E

Sektori keskmine

3.101

35.664

Kasumimarginaal

-8.517

Töötajad

900

EBITDA

-131M

1.6M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+68.75% upside

Turustatistika

By TradingEconomics

Turukapital

111M

434M

Eelmine avamishind

8.96

Eelmine sulgemishind

7.82

Uudiste sentiment

By Acuity

12%

88%

18 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Emergent BioSolutions Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. sept 2025, 17:03 UTC

Suurimad hinnamuutused turgudel

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16. sept 2025, 16:49 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

GD Culture Shares Drop After Deal for Pallas Capital

16. sept 2025, 16:11 UTC

Suurimad hinnamuutused turgudel

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16. sept 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16. sept 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16. sept 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16. sept 2025, 21:10 UTC

Omandamised, ülevõtmised, äriostud

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16. sept 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16. sept 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16. sept 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

16. sept 2025, 20:25 UTC

Tulu

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16. sept 2025, 20:24 UTC

Tulu

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16. sept 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16. sept 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16. sept 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16. sept 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16. sept 2025, 18:40 UTC

Omandamised, ülevõtmised, äriostud

Details Emerge on U.S.-China TikTok Deal -- WSJ

16. sept 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16. sept 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16. sept 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16. sept 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16. sept 2025, 16:53 UTC

Tulu

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16. sept 2025, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

16. sept 2025, 16:15 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Commodities Roundup: Market Talk

16. sept 2025, 16:09 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Energy Roundup: Market Talk

16. sept 2025, 16:09 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16. sept 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. sept 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16. sept 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16. sept 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Emergent BioSolutions Inc Prognoos

Hinnasiht

By TipRanks

68.75% tõus

12 kuu keskmine prognoos

Keskmine 13.5 USD  68.75%

Kõrge 15 USD

Madal 12 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Emergent BioSolutions Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

4.95 / N/AToetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

18 / 371 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat